Endra Life Sciences Inc Stock Price, News & Analysis

ENDRA Life Sciences Inc. (NASDAQ: NDRA) will announce its third-quarter financial results on November 15, 2021, after the market close. Following the release, management will conduct a conference call at 4:30 p.m. Eastern Time to discuss results and recent developments. Investors can pre-register for the call or access a webcast via the company's Investor Relations page. ENDRA specializes in Thermo Acoustic Enhanced UltraSound (TAEUS), aiming to provide cost-effective diagnostic imaging, particularly for liver conditions affecting over one billion people globally.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) has been granted U.S. Patent 11147067, titled “Method And System For Monitoring Tissue Temperature,” enhancing its innovation in Thermo Acoustic Enhanced UltraSound (TAEUS®). This patent complements the earlier U.S. Patent 10631734, both focusing on tissue temperature monitoring during surgical procedures. ENDRA is progressing towards the commercial launch of TAEUS® in Europe and awaits FDA regulatory response for the U.S. market, while its intellectual property portfolio expands to 87 patents, crucial for its strategy in addressing unmet medical needs.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) will present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021, at 2:00 p.m. Eastern Time. Management will also hold virtual one-on-one meetings with investors throughout the day. ENDRA is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which offers cost-effective tissue visualization comparable to MRI, initially targeting liver fat measurement for assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). For further details, visit www.endrainc.com.

ENDRA Life Sciences (NASDAQ:NDRA) will participate in two virtual investment conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, where a recorded presentation will be available on demand starting September 13. The second is the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 20-23, with a live presentation on September 21 at 1:15pm ET. ENDRA specializes in Thermo Acoustic Enhanced UltraSound (TAEUS), a technology aimed at visualizing tissue at a fraction of MRI costs, initially focusing on liver health diagnostics.

ENDRA Life Sciences (NASDAQ:NDRA) reported its second-quarter 2021 results, highlighting significant operational developments. The company continues patient screenings at Rocky Vista University and anticipates the University of Pittsburgh Medical Center to start soon. ENDRA initiated in-person sales for its TAEUS system in Europe, supported by a growing patent portfolio of 87 global assets. Despite a net loss of $3.2 million and operating expenses rising to $3.2 million, cash reserves stand at $14 million. CEO Francois Michelon expressed optimism for FDA clearance in 2021, despite potential delays.

ENDRA Life Sciences Inc. (NASDAQ:NDRA) will report its Q2 2021 financial results on August 12, 2021, following the market close. The management will host a conference call and webcast at 4:30 p.m. ET to discuss results and recent corporate updates. The company is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at visualizing tissue at a fraction of MRI costs, particularly for assessing liver conditions like NAFLD and NASH. The technology is compatible with numerous existing ultrasound systems.

ENDRA Life Sciences Inc. (NASDAQ:NDRA) will participate in A.G.P.'s Virtual MedTech Summer Conference on July 29, 2021. This event includes 1-on-1 virtual investor meetings, allowing investors to connect with the management team. ENDRA is a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a technology that visualizes tissue at a fraction of MRI costs. TAEUS® targets chronic liver conditions like Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), affecting over one billion people globally.

ENDRA Life Sciences (NASDAQ:NDRA) has expanded its patent portfolio with three newly issued patents from the USPTO related to its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. The patents include methods for estimating liver fat content, determining material parameters, and monitoring temperature during thermal ablation. This growth in intellectual property, now totaling 86 assets, is aimed at enhancing the commercial application of TAEUS®, which targets significant medical challenges like Non-Alcoholic Fatty Liver Disease. The company emphasizes protecting its innovations in key global markets.

ENDRA Life Sciences (NASDAQ:NDRA) has appointed Irina Pestrikova as the new Senior Director of Finance and Principal Financial Officer, effective June 18, 2021. She will take over the responsibilities previously held by David Wells, who is departing to pursue another opportunity. Pestrikova has been with ENDRA since 2014, contributing to its financial planning and accounting functions. Wells will assist in the transition until September 2021.

This leadership change comes as ENDRA continues to innovate with its Thermo Acoustic Enhanced UltraSound (TAEUS) technology for liver and other clinical applications.